Categories

I-CARE Early Covid (3) I-CARE Flu and RSV (1) I-PREVENT (28) I-RECOVER Long Covid (3) I-RECOVER Post-Vaccine (3) MATH+ (20)

Tags

25-hydroxyvitamin D (2) 25‐HYDROXY VITAMIN D (2) Ambulatory treatment (2) Anti-inflammatory (2) Anti-Inflammatory Agents (1) Anticoagulant (2) Antimicrobial Cationic Peptides (1) Antiparasitic Agents (3) Antiviral (2) Ascorbic Acid (3) Calcifediol (1) Collagen (1) Coronavirus (2) COVID-19 (23) Dithiothreitol (1) Endothelial Barrier (1) Endothelial Permeability (1) Epidemiology (2) Ergocalciferols (1) Famotidine (7) Fixed drug eruption (1) Glucocorticosteroids (3) Heparanase (2) Human immunodeficiency virus (HIV) (1) Hydroxychloroquine (2) Inflammation (4) ivermectin (18) Melatonin (13) Methylprednisol (2) Nitric Oxide (1) Omicron (6) Onchocerciasis (1) pharmacokinetics (1) Pneumonia (2) SARS-CoV-2 (20) Sars-CoV2 (2) Sepsis (3) Septic (2) Spike Protein (5) Stevens–Johnson syndrome (SJS) (1) Tempol (1) viral infection (3) Vitamin C (3) Vitamin D (6) vitamin D 2 (1)

  • Reference: Efficacy of a low dose of melatonin as an adjunctive therapy in hospitalized patients with COVID-19: A randomized, double-blind clinical trial

    Published On: June 23, 2021

    Background: Melatonin has been known as an anti-inflammatory agent and immune modulator that may address progressive pathophysiology of coronavirus disease 2019 (COVID-19).

    Categories: MATH+

    Tags: Adjunctive therapy, Melatonin